Long term extension trials of ACT (Active Ulcerative Colitis 1 & 2) conducted in the United States and Europe show moderately to severely active ulcerative colitis (UC) patients who had responded to REMICADE (infliximab) in earlier trials maintained improvement in their clinical symptoms for up to two years.
The trials were conducted under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the University Hospital Vienna, Austria. The data measured by the Physician's Global Assessment (PGA), reveals that in patients who completed follow-up through week 56 of the extension trials, 92 percent reported mild or no disease activity; in patients followed through week 104, 97 percent reported mild or no disease activity.
At week 0 of the ACT extension trials, 76 percent of 229 responder patients enrolled had mild or no disease activity, as indicated by a PGA score of 0 or 1, and 41 percent had no disease activity (PGA score of 0). At week 56, 92 percent of those patients remaining in the extension trials (n=181) had mild or no disease activity, and 61 percent had no disease activity. At week 104, 97 percent of those patients remaining in the extension trials (n=97) had mild or no disease activity, and 75 percent had no disease activity.
"The data demonstrate the sustained efficacy of REMICADE for many patients with UC," said co-principle investigator Walter Reinisch, M.D., of the University Hospital Vienna, Austria. "Because UC is a chronic condition, many patients live with cycles of recurring flares. This can greatly hinder a person's social and professional life. The availability of therapies that quickly reduce symptoms and maintain response and remission long term is a significant benefit to patients."
Separate data also presented at DDW today show the significant impact of UC on patients' productivity, employment and social activities. A survey of 1,000 patients whPage: 1 2 3 Related medicine news :1
. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder2
. Remicade Therapy Effective in Treating Severe Psoriasis3
. Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohns Disease4
. Responders On 9/11 Face Health Risks5
. More Money to Flow for First Responders at Ground Zero6
. Maintaining warmth during cold7
. Maintaining Weight Loss with Drugs 8
. Maintaining a Pharma index could help track price fluctuations 9
. Brain Plays Vital Role In Maintaining Bone Density10
. The Two-In-One Estrogen Therapy For Managing Menopause And Maintaining Healthy Skin11
. Beauty Queens Urge On The Importance Of Maintaining Bone Integrity